Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1

OBJECTIVES: PsA is a heterogeneous disease that impacts many aspects of social and mental life, including quality of life. Risankizumab, an antagonist specific for IL-23, is currently under investigation for the treatment of adults with active PsA. This study evaluated the impact of risankizumab vs...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristensen, Lars Erik, Soliman, Ahmed M, Papp, Kim, White, Douglas, Barcomb, Lisa, Lu, Wenjing, Eldred, Ann, Behrens, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891435/
https://www.ncbi.nlm.nih.gov/pubmed/35801915
http://dx.doi.org/10.1093/rheumatology/keac342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891435/
https://www.ncbi.nlm.nih.gov/pubmed/35801915
http://dx.doi.org/10.1093/rheumatology/keac342

Ejemplares similares